U.S. Type 1 Diabetes Treatment Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Type 1 Diabetes Treatment Market
- ✓Market Size 2024: USD 14.8 billion
- ✓Market Size 2032: USD 26.7 billion
- ✓CAGR: 7.5%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Device Portfolio Priority: Device investors should prioritise automated insulin delivery platforms with FDA clearance across paediatric age bands by Q4 2025. Contract with state Medicaid programmes now, because CMS competitive bidding will reset Medicare reimbursement before 2028.
Type 1 Diabetes Treatment in the U.S.: Market Overview
The U.S. type 1 diabetes treatment market was valued at USD 14.8 billion in 2024 and is forecast to reach USD 26.7 billion by 2032 at a 7.5% CAGR. It comprises insulin, continuous glucose monitors (CGMs), automated insulin delivery (AID) systems, and the disease-modifying drug teplizumab. Published 2021 prevalence estimates place roughly 1.6 million Americans with the condition, many diagnosed in childhood, and federal payers fund most of the volume.
Government has been the dominant force in pricing and coverage, operating through the Medicare Part D benefit, Medicaid rebate rules and the Inflation Reduction Act. Private sector innovation has led in devices, with Dexcom, Abbott, Insulet and Tandem Diabetes Care commercialising CGM and AID products before most federal coverage decisions. Insulin supply remains concentrated in three manufacturers, Eli Lilly, Novo Nordisk and Sanofi, which control most basal and bolus volume.
Policy-Driven Growth in U.S. Type 1 Diabetes Care
The Inflation Reduction Act, Section 11406, capped Medicare Part D insulin cost-sharing at USD 35 per month from 1 January 2023, administered by the Centers for Medicare and Medicaid Services (CMS). Removing this cost barrier raises refill adherence, which expands dispensed volume among older adult patients. Separately, CMS revised Local Coverage Determination L33822 in 2023 to cover CGMs for any beneficiary using insulin, converting diagnostic-led prescribing into routine monitoring demand.
The Medicare Drug Price Negotiation Program, created by the IRA, selected Novo Nordisk's NovoLog and Fiasp in its first cycle, with negotiated prices effective 1 January 2026. The mechanism resets the Medicare maximum fair price, compressing list-to-net spreads and pressuring commercial rebate structures. Lower net prices then widen access in Medicaid and employer plans. Additionally, FDA approval of teplizumab (Tzield) in November 2022 gave payers a delay-of-onset product, which Sanofi now commercialises after acquiring Provention Bio in 2023.
Regulatory Barriers and Compliance Costs
Insulin products are licensed as biologics under Section 351 of the Public Health Service Act, as amended by the Biologics Price Competition and Innovation Act of 2009, and enforced by the FDA's Center for Drug Evaluation and Research. Biosimilar entrants must demonstrate interchangeability, a designation Semglee from Biocon Biologics and Mylan received in 2021 after switching studies that add substantial clinical cost. Device makers face the FDA's 510(k) and premarket approval pathways, which typically require a year or more before clearance.
Medicare device suppliers must hold DMEPOS accreditation from CMS-approved accreditors and meet supplier standards under 42 CFR 424.57. Competitive bidding adds reimbursement risk, because winning bids set Medicare rates for contract periods. Manufacturers also face HRSA-administered 340B Drug Pricing Program rules, where contract pharmacy restrictions create compliance complexity for insulin distribution across covered entities and retail partners.
Policy-Created Opportunities in U.S. Type 1 Diabetes Care
The Medicare USD 35 cap and the negotiated NovoLog price create an opening for interchangeable insulin aspart and glargine biosimilars. Entrants that secure interchangeability designation from the FDA can win formulary placement through PBM tender processes, capturing volume that originator manufacturers have lost through rebate-driven exclusions. Cash-pay manufacturer programmes at USD 35 per month also create a parallel channel for uninsured and high-deductible patients.
CMS's DMEPOS competitive bidding round, covering CGMs and insulin pumps, rewards suppliers with scalable, lower-cost manufacturing. Vertex's zimislecel, an islet cell therapy holding FDA Regenerative Medicine Advanced Therapy (RMAT) designation under the 21st Century Cures Act, is scheduled for global submissions from 2026 through CBER. Early adopters with cell therapy reimbursement pathways will shape Medicare coding and payment decisions for one-time therapies.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 14.8 billion |
| Market Size 2032 | USD 26.7 billion |
| Growth Rate (CAGR) | 7.5% |
| Most Critical Decision Factor | Medicare and commercial payer formulary placement |
| Largest Region | South Census Region |
| Competitive Structure | Oligopolistic in insulin; fragmented in devices |
Leading Market Participants
- Eli Lilly and Company
- Novo Nordisk
- Sanofi
- Medtronic
- Dexcom
- Abbott Laboratories
- Insulet Corporation
- Tandem Diabetes Care
- Biocon Biologics
- Beta Bionics
Regulatory and Policy Environment
The governing statute is the Inflation Reduction Act of 2022 (Public Law 117-169), which amended Title XVIII of the Social Security Act to cap Part D insulin cost-sharing and created the Medicare Drug Price Negotiation Program. CMS administers both provisions, while the FDA regulates insulin biologics under the Public Health Service Act and devices under the Federal Food, Drug, and Cosmetic Act. Device suppliers must maintain DMEPOS accreditation, and Part D plans must apply the USD 35 cap without deductibles.
Upcoming changes are dated. The Part D out-of-pocket cap rises to USD 2,100 in 2026, negotiated NovoLog and Fiasp prices take effect on 1 January 2026, and the next DMEPOS competitive bidding round, covering CGMs and insulin pumps, sets Medicare rates from 2028. The FTC's September 2024 administrative complaint against Caremark, Express Scripts and OptumRx over insulin rebates remains active. Compared with peers, the U.S. relies on payer-level price controls, whereas Canada's Pharmacare Act (2024) channels insulin and diabetes supplies through provincial bilateral agreements, and the UK sets prices through NHS England tariffs.
Long-Term Policy Outlook for Type 1 Diabetes in the U.S.
By 2032, Medicare negotiation will extend beyond insulin analogues into diabetes devices as CMS scopes future selection cycles, expanding federal price-setting authority across the market. Biosimilar insulin aspart and glargine will hold a growing share of Medicare volume as interchangeability designations convert formulary positions. Net pricing will therefore shift value toward low-cost entrants and away from rebate-heavy originators.
Congressional PBM reform, including delinking PBM compensation from list prices, will reshape rebate economics by the early 2030s. Vertex's zimislecel, with submissions from 2026, will establish a one-time cell therapy channel requiring new Medicare coding and outcomes-based payment models. Teplizumab adoption will depend on CMS coverage of Stage 3 screening programmes, which will determine whether delay-of-onset therapy becomes a standard of care.
Frequently Asked Questions
Market Segmentation
- Rapid-acting insulin
- Long-acting insulin
- Continuous glucose monitors
- Automated insulin delivery systems
- Disease-modifying therapies
- Medicare Part D
- Medicaid
- Commercial insurance
- Cash-pay manufacturer programmes
- Retail pharmacies
- Mail-order pharmacies
- Specialty pharmacies
- DME suppliers
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.